Business Context and Reporting Period
This Form 8-K filing by Drugs Made In America Acquisition II Corp. (DMII), a Cayman Islands-based special purpose acquisition company, reports on corporate governance changes occurring between October 8, 2025, and November 17, 2025. The company is an emerging growth company with securities trading on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation:
- Annual Compensation: $42,000 per year for the new Chief Financial Officer services.
- Monthly Compensation: $3,500 per month paid to Titan Advisory Services LLC.
- Equity Grant: 100,000 ordinary shares to be transferred to the new CFO upon engagement.
Material Changes
The primary material change reported is the turnover of the Principal Financial and Accounting Officer:
- Resignation: Glenn Worman resigned as Chief Financial Officer effective October 8, 2025. The resignation was not due to any disagreement with the company regarding operations, policies, or practices.
- Appointment: Saleem Elmasri was appointed as the new Chief Financial Officer and principal financial and accounting officer, effective November 17, 2025.
Outlook, Risks, and Management Commentary
Management Commentary: The company highlighted Mr. Elmasri's 20 years of experience in financial and management consulting, including roles at PricewaterhouseCoopers and various boutique advisory firms, with a specific focus on the Life Sciences and Pharmaceutical industry. He will serve as Managing Partner at Titan Advisory Services LLC while providing CFO services to DMII.
Agreements: Mr. Elmasri is expected to enter into standard Indemnity, Letter, and Registration Rights Agreements consistent with other directors and officers. No family relationships exist between Mr. Elmasri and current directors or officers.
Risks and Contingencies: The filing does not disclose new material risks, contingencies, or unusual items beyond the standard executive transition.
Investor Verification Checklist
- Verify the effective date of the new CFO's appointment (November 17, 2025) against the resignation date of the previous CFO (October 8, 2025) to assess the duration of the interim period.
- Confirm the transfer of the 100,000 ordinary shares to Saleem Elmasri and the impact on existing share capital.
- Review the Master Services Agreement with Titan Advisory Services LLC for any additional terms not summarized in the 8-K.
- Check subsequent filings for any financial reporting delays or restatements resulting from the leadership transition.